DexCom, Inc. (DXCM) 47th Annual Raymond James Institutional Investor Conference March 2, 2026 1:05 PM ESTCompany ParticipantsJereme Sylvain - Executive ...

The Dexcom CEO will lead the lobbying group’s sector representing diabetes tech companies around the world.

The company has integrated its Eversense 365 implant with Sequel Med Tech’s insulin delivery system to automate the management of Type 1 diabetes.

Senseonics rolls out Eversense 365 integrated with Sequel's twiist AID system, aiming to boost CGM adoption with its year-long wear advantage.

The workflow-native platform brings total funding to $40 million as leading firms adopt its end-to-end infrastructure for ...

The "Glucose Goddess" built a brand around her blood sugar balancing hacks. She said a few swaps to her diet boosted her mood ...

NYC- and Paris-based DeepIP reaches $40M in total funding, with tenfold ARR growth in 18 months, as workflow-native AI becomes the standard for modern patent operations. $25M Series B co-led by tech ...

Rimidi's platform has demonstrated measurable impact on clinical outcomes, patient engagement and overall cost of care, including one healthcare partner achieving an average 2.8% reduction in ...

No one has had a Synchron brain-computer interface longer than Rodney Gorham. He's still finding new ways to use it.

Goal of Caliper Accelerator is to enable more consistent integration of device data into EHRs, analytics platforms, and ...

Insulet stock is up on fourth-quarter results ahead of consensus, with company leaders talking about talent, technology, and momentum.

One underappreciated reason why I feel DXCM could potentially gain more favorable interest is because its long-suffering ...